Vancomycin (Firvanq, Tyzavan, Vancocin) — 2026 Medicare Part D coverage
vancomycin — sold as Firvanq, Tyzavan, Vancocin: 13 forms appear in Medicare Part D formularies for 2026. This page reports what plans filed with CMS; it does not recommend a plan.
Which plans in your county cover vancomycin?
Pick a county to see every Medicare Advantage plan filed there and every stand-alone Part D plan in its region, with this drug's tier, restrictions and tier cost sharing.
How to read drug coverage
Tier is the cost-sharing tier the plan assigned the drug in its CMS formulary filing; lower tiers usually cost less. PA = prior authorization, ST = step therapy (try another drug first), QL = quantity limit. Not on formulary means the plan did not list this exact form; the plan may cover another strength or a formulary exception may be possible. Cost sharing is the plan's initial-coverage amount for the tier as filed with CMS; the deductible, the $2,100 annual out-of-pocket cap, the $35 insulin cap and negotiated prices for selected drugs can change what you actually pay. Formularies change during the year; the plan's formulary document and Medicare.gov govern.
What the star rating under each Medicare Advantage plan means
What the star rating means. CMS rates every Medicare Advantage contract (the "H" number in the plan ID — all plans under it share the rating) on a 1-to-5 scale each October, from about 40 measures of care quality, member experience, complaints and appeals, customer service and, for plans with drug coverage, drug safety and pricing. The 2026 rating is largely based on performance measured in 2024.
5 Excellent4 Above average3 Average2 Below average1 Poor
Not rated means CMS published no overall rating — usually a contract too new to be measured or with too few members ("not enough data"); it is not a low score. A 5-star contract can be joined outside the normal enrollment windows (the 5-star Special Enrollment Period, Dec 8 – Nov 30). Medicare.gov flags contracts rated below 3 stars for three years running as low-performing. Stars describe the contract's past performance as CMS measured it; they are not a recommendation, and they do not tell you whether a plan's network, drugs or costs fit you.
Forms and strengths in 2026 formularies
| Form | Formularies listing it | Most common tier | PA | ST | QL |
|---|---|---|---|---|---|
| vancomycin 1 GM Injection generic · RxCUI 1807513 | 328 (100%) | 4 | 0 | 0 | 29 |
| vancomycin HCl 125 MG Oral Capsule generic · RxCUI 313570 | 328 (100%) | 4 | 27 | 1 | 290 |
| vancomycin HCl 250 MG Oral Capsule generic · RxCUI 313571 | 327 (100%) | 4 | 26 | 1 | 290 |
| vancomycin 500 MG Injection generic · RxCUI 1807516 | 326 (99%) | 4 | 0 | 0 | 29 |
| vancomycin 100 MG/ML Injectable Solution generic · RxCUI 239209 | 323 (98%) | 4 | 2 | 0 | 28 |
| vancomycin 750 MG Injection generic · RxCUI 1807518 | 321 (98%) | 4 | 0 | 0 | 28 |
| vancomycin 25 MG/mL Oral Solution generic · RxCUI 2000127 | 50 (15%) | 4 | 0 | 0 | 9 |
| vancomycin 50 MG/mL Oral Solution generic · RxCUI 2000134 | 39 (12%) | 4 | 0 | 0 | 11 |
| TYZAVAN 1 GM in 200 ML Injection brand · RxCUI 2725135 | 25 (8%) | 4 | 0 | 0 | 0 |
| FIRVANQ 25 MG/mL Oral Solution brand · RxCUI 2000133 | 5 (2%) | 3 | 0 | 0 | 2 |
| FIRVANQ 50 MG/mL Oral Solution brand · RxCUI 2000136 | 5 (2%) | 3 | 0 | 0 | 2 |
| Vancocin 125 MG Oral Capsule brand · RxCUI 201848 | 1 (0%) | 4 | 0 | 0 | 0 |
| Vancocin 250 MG Oral Capsule brand · RxCUI 201849 | 1 (0%) | 5 | 0 | 0 | 0 |
Counts are formularies (of 328) in the CMS file that list the form, and how many of those apply prior authorization (PA), step therapy (ST) or a quantity limit (QL). Many plans share one formulary, so plan counts in a county will differ.
How to read drug coverage
Tier is the cost-sharing tier the plan assigned the drug in its CMS formulary filing; lower tiers usually cost less. PA = prior authorization, ST = step therapy (try another drug first), QL = quantity limit. Not on formulary means the plan did not list this exact form; the plan may cover another strength or a formulary exception may be possible. Cost sharing is the plan's initial-coverage amount for the tier as filed with CMS; the deductible, the $2,100 annual out-of-pocket cap, the $35 insulin cap and negotiated prices for selected drugs can change what you actually pay. Formularies change during the year; the plan's formulary document and Medicare.gov govern.
What the star rating under each Medicare Advantage plan means
What the star rating means. CMS rates every Medicare Advantage contract (the "H" number in the plan ID — all plans under it share the rating) on a 1-to-5 scale each October, from about 40 measures of care quality, member experience, complaints and appeals, customer service and, for plans with drug coverage, drug safety and pricing. The 2026 rating is largely based on performance measured in 2024.
5 Excellent4 Above average3 Average2 Below average1 Poor
Not rated means CMS published no overall rating — usually a contract too new to be measured or with too few members ("not enough data"); it is not a low score. A 5-star contract can be joined outside the normal enrollment windows (the 5-star Special Enrollment Period, Dec 8 – Nov 30). Medicare.gov flags contracts rated below 3 stars for three years running as low-performing. Stars describe the contract's past performance as CMS measured it; they are not a recommendation, and they do not tell you whether a plan's network, drugs or costs fit you.